

Highly Efficient and Enantioselective Synthesis of Carbocyclic Nucleoside Analogs Using Selective Early Transition Metal Catalysis


Luis E. Martínez,¹ William A. Nugent,^{*,2} and Eric N. Jacobsen^{*,1}

Harvard University, Department of Chemistry and Chemical Biology, Cambridge, Massachusetts 02138, and DuPont Central Research & Development, Wilmington, Delaware 19880

Received July 2, 1996

The development of synthetic routes to carbocyclic nucleoside analogs has attracted considerable attention, due partly to the interesting biological activity of these compounds and also to the persistent challenges associated with constructing substituted 5-membered carbocycles with defined relative and absolute stereochemistry.³ Particularly noteworthy members of this class of compounds include the naturally-occurring carbocyclic adenosine analog (–)-aristeromycin (**1**), the biosynthesis⁴ and biological activity⁵ of which have been subject to recent intensive scrutiny; the related natural product (–)-3'-deoxyaristeromycin (**2**);⁶ (–)-carbovir (**3**), a selective inhibitor of HIV reverse transcriptase *in vitro*;⁷ and the structurally related (–)-1592U89 succinate (**4**), which has been reported to have a higher oral bioavailability than carbovir and is currently in clinical trials for the treatment of HIV infection (Figure 1).⁸

Our two groups recently uncovered effective catalysts for the highly selective synthesis and manipulation of 5-membered cyclic structures (Figure 2). Complex **5**,



X = OH: (–)-aristeromycin (**1**) Y = OH: (–)-carbovir (**3**)
X = H: (–)-3'-deoxyaristeromycin (**2**) Y = NH: 1592U89 (**4**)

Figure 1.




Figure 2.




Figure 3.

generated *in situ* by the combination of WOCl₄ and 2,6-dibromophenol, is a useful and inexpensive catalyst for the ring-closing metathesis (RCM) of acyclic dienes to afford 5- and 6-membered cyclic compounds.⁹ The (salen)Cr complex **6** has been identified as a catalyst for the asymmetric ring-opening (ARO) of meso and racemic epoxides by TMSN₃,¹⁰ with particularly high enantioselectivity displayed for the opening of epoxides fused to 5-membered rings. The sequential application of these two catalytic transformations, along with an intermediary epoxidation reaction, could constitute an efficient method for the conversion of simple dienes to cyclic 1,2-amino alcohols wherein a new C–C bond has been constructed and two contiguous stereogenic centers have been established with high relative and absolute control (Figure 3). In this paper, the power of this strategy is illustrated in the efficient synthesis of key intermediates leading to the carbocyclic nucleoside analog structures outlined in Figure 1.

The key intermediate epoxide **10** needed for this synthetic approach was obtained in four steps from commercially available diethyl diallylmalonate (Scheme 1). Decarboxylation followed by RCM with catalyst **5** under previously reported conditions⁹ produced the 3-cyclopentenecarboxylic ester **8** in 61% overall yield after distillation. Epoxidation of **8** was effected with *m*-chloroperoxybenzoic acid (*m*-CPBA), providing a 3:1 mixture of anti- and syn-isomers.¹¹ The pure *anti*-epoxide **9** was isolated in 70% yield after chromatogra-

(9) Nugent, W. A.; Feldman, J.; Calabrese, J. C. *J. Am. Chem. Soc.* **1995**, *117*, 8992.

(10) (a) Martínez, L. E.; Leighton, J. L.; Carsten, D. H.; Jacobsen, E. N. *J. Am. Chem. Soc.* **1995**, *117*, 5897. (b) Larrow, J. F.; Schaus, S. E.; Jacobsen, E. N. *J. Am. Chem. Soc.* **1996**, *118*, 7420.

(11) For epoxidation of related compounds, see: (a) Agrofoglio, L.; Condom, R.; Guedj, R. *Tetrahedron Lett.* **1992**, *33*, 5503. (b) Norman, M. H.; Almond, M. R.; Reitter, B. E.; Rahim, S. G. *Synth. Commun.* **1992**, *22*, 3197.

(1) Harvard University.

(2) DuPont Central Research & Development.

(3) For recent reviews, see: (a) Borthwick, A. D.; Biggadike, K. *Tetrahedron* **1992**, *48*, 571. (b) Huryn, D. M.; Okabe, M. *Chem. Rev.* **1992**, *92*, 1745. Asymmetric synthesis: (c) Trost, B. M.; Stenkamp, D.; Pulley, S. R. *Chem. Eur. J.* **1995**, *1*, 568. (d) Campbell J. A.; Lee, W. K.; Rapoport, H. *J. Org. Chem.* **1995**, *60*, 4602. (e) Park, K. H.; Rapoport, H. *J. Org. Chem.* **1994**, *59*, 394. (f) Csuk, R.; Dörr, P. *Tetrahedron* **1995**, *51*, 5789. (g) Handa, S.; Earlam, G. J.; Geary, P. J.; Hawes, J. E.; Phillips, G. T.; Pryce, R. J.; Ryback, G.; Shears, J. H. *J. Chem. Soc., Perkin Trans. 1* **1994**, 1885. (h) Nokami, J.; Matsuura, H.; Nakasima, K.; Shibata, S. *Chem. Lett.* **1994**, 1071.

(4) (a) Jenkins, G. N. *Chem. Soc. Rev.* **1995**, 169. (b) Hill, J. M.; Jenkins, G. N.; Rush, C. P.; Turner, N. J.; Willetts, A. J.; Buss, A. D.; Dawson, M. J.; Rudd, B. A. M. *J. Am. Chem. Soc.* **1995**, *117*, 5391.


(5) (a) Mayers, D. L.; Mikovits, J. A.; Joshi, B.; Hewlett, I. K.; Estrada, J. S.; Wolfe, A. D.; Garcia, G. E.; Doctor, B. P.; Burke, D. S.; Gordon, R. K.; Lane, J. R.; Chiang, P. K. *Proc Natl. Acad. Sci. U.S.A.* **1995**, *92*, 215. (b) Mizutani, Y.; Masuoka, S.; Imoto, M.; Kawada, M.; Umezawa, K. *Biochem. Biophys. Res. Commun.* **1995**, *207*, 69. (c) Wolfe, M. S.; Lee, Y.; Bartlett, W. J.; Borcherding, D. R.; Borcharadt, R. T. *J. Med. Chem.* **1992**, *35*, 1782. (d) Herdewijn, P.; Balzarial, J.; De Clercq, E.; Vanderhaeghe, H. *J. Med. Chem.* **1985**, *28*, 1385.

(6) (a) Agrofoglio, L.; Condom, R.; Guedj, R.; Challand, R.; Selway, J. *Tetrahedron Lett.* **1993**, *34*, 6271. (b) Palmer, C. F.; Parry, K. P.; Roberts, S. M. *J. Chem. Soc., Perkin Trans. 1* **1991**, 484. (c) Shealy, Y. F.; O'Dell, C. A.; Arnett, G. J. *J. Med. Chem.* **1987**, *30*, 1090. (d) Hronowski, L. J. J.; Szarek, W. A. *Can. J. Chem.* **1986**, *64*, 1620.


(7) (a) Miller, W. H.; Daluge, S. M.; Garvey, E. P.; Hopkins, S.; Reardon, J. E.; Boyd, F. L.; Miller, R. L. *J. Biol. Chem.* **1992**, *267*, 21220. (b) Mahony, W. B.; Domin, B. A.; Daluge, S. M.; Miller, W. H.; Zimmerman, T. P. *J. Biol. Chem.* **1992**, *267*, 19792. (c) Orr, D. C.; Figueiredo, H. T.; Mo, C. L.; Penn, C. R.; Cameron, J. M. *J. Biol. Chem.* **1992**, *267*, 4177. (d) Vince, R.; Brownell, J. *Biochem. Biophys. Res. Commun.* **1990**, *168*, 912. (e) Vince, R.; Hua, M. *J. Med. Chem.* **1990**, *33*, 17.

(8) (a) Kimberlin, D. W.; Coen, D. M.; Biron, K. K.; Cohen, J. I.; Lamb, R. A.; McKinlay, M.; Emin, E. A.; Whitley, R. J. *Antiviral Res.* **1995**, *26*, 369. (b) Good, S. S.; Daluge, S. M.; Ching, S. V.; Ayers, K. M.; Mahony, W. B.; Faletto, M. B.; Domin, B. A.; Owens, B. S.; Dornsife, R. E.; McDowell, J. A.; LaFon, S. W.; Symonds, W. T. *Antiviral Res.* **1995**, *26*, A229.

Scheme 1



Scheme 2



phy. Although molybdenum-catalyzed epoxidation of **8** with alkyl hydroperoxides provided superior diastereoselectivity (up to 12:1 anti/syn), competing decomposition of the products resulted in diminished isolated yields of the desired epoxide. Reduction of ester **9** with LiAlH_4 and conversion to the *tert*-butyldimethylsilyl (TBS) ether afforded **10** in high yield with no detectable epoxide-opening.

Enantioselective ring opening of epoxide **10** with TMSN_3 catalyzed by (*S,S*)-**6b** proceeded quantitatively to a single product, providing azido silyl ether **11** in 95% yield and in 96% ee after purification by distillation (Scheme 2).¹² Hydrogenation of azido silyl ether **11** over Lindlar's catalyst provided the enantiomerically enriched 3'-deoxyaristeromycin precursor **12** in 93% yield.^{6c}

Synthesis of the carbocyclic cores of compounds **1**, **3**, and **4** required elimination of the TMS ether from **11**. Camphorsulfonic acid (CSA)-catalyzed selective removal of the trimethylsilyl group was followed by tosylation of the resultant secondary alcohol to produce activated intermediate **13**. Attempts to effect elimination directly from **13** using a variety of Brønsted bases either failed altogether or provided very poor yields of the desired alkene **14**. In contrast, nucleophilic tosylate displacement by sodium phenyl selenide¹³ and subsequent oxida-

tive elimination of the resulting selenide proved effective and afforded azido cyclopentene **14** in 81% yield. Synthesis of the carbocyclic cores of (–)-carbovir (**3**) and (–)-1592U89 (**4**) was provided by reduction of **14** to amine **15**.¹⁴ Synthesis of the core structure of (–)-aristeromycin (**1**) was achieved by a highly diastereoselective OsO_4 -catalyzed dihydroxylation¹⁵ of **14** followed by azide reduction to provide amino diol **16** in 75% yield over two steps.¹⁶

The approach to carbocyclic nucleoside analogs outlined herein is rendered efficient by virtue of the successive use of catalytic reactions that are not only highly-selective and clean but also afford product with minimal generation of waste byproducts. Application of these early-transition metal-catalyzed reactions to a range of other targets of synthetic and biological interest is under active investigation in our laboratories.

Experimental Section

3-Cyclopentenecarboxylic Acid, Ethyl Ester (8). The reported procedure for the decarboxylation of diethyl diallylmalonate followed by ring-closing metathesis of the resulting diene (**7**)⁹ was followed with minor modifications: A 500 mL flask was charged with tungsten oxychloride (0.813 g, 2.38 mmol), 2,6-dibromophenol (1.20 g, 4.76 mmol), and toluene (25 mL), and the resulting mixture was heated to reflux for 1 h under N_2 . Volatile materials were removed under reduced pressure, and the solid residue was kept under vacuum for 30 min. The flask was then charged with dry toluene (160 mL), tetraethyllead (1.54 g, 4.76 mmol), and **7** (22.0 g, 131.0 mmol), and the mixture was heated at 90 °C for 1.5 h under N_2 . After being cooled to room temperature, the mixture was filtered through a 1 cm pad of silica and the silica pad was rinsed with *tert*-butyl methyl ether (TBME) (300 mL). The organic layers were combined and washed with 1% NaOH (2 × 300 mL), water (2 × 200 mL), and saturated NH_4Cl (200 mL). After drying (MgSO_4) and removal of the solvent under reduced pressure, distillation (60–64 °C, 15 Torr) provided **8** (15.60 g, 85%) as a colorless liquid: $^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ 5.66 (s, 2H), 4.15 (q, $J = 7.1$ Hz, 2H), 3.10 (quin, $J = 8.3$ Hz, 1H), 2.65 (d, $J = 7.8$ Hz, 4H) 1.26 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C NMR}$ (CDCl_3 , 100 MHz) δ 176.1, 128.9, 60.4, 41.5, 36.3, 14.2.

trans-3,4-Epoxy-cyclopentenecarboxylic Acid, Ethyl Ester (9). To a cooled (0 °C) solution of cyclopentene ester **8** (17.10 g, 122.00 mmol) in CH_2Cl_2 (260 mL), *m*-chloroperbenzoic acid (27.54 g, 159.60 mmol) was added in three portions. The reaction was allowed to warm to room temperature and after 4 h filtered to remove the precipitated *m*-chlorobenzoic acid. The solids were rinsed with CH_2Cl_2 (150 mL), and the combined organic layers were then washed with saturated NaHCO_3 (200 mL), 10% Na_2SO_3 (200 mL), and saturated NaHCO_3 (200 mL). The organic phase was dried (MgSO_4), filtered, and concentrated to give 20.5 g of a clear liquid identified by $^1\text{H NMR}$ to be a 3:1 mixture of **9** and its *cis* diastereomer; purification by flash chromatography provided **9** in pure form (13.43 g, 70.5%): TLC $R_f = 0.27$ – 0.28 (1:4 EtOAc:hexanes); $^1\text{H NMR}$ (CDCl_3 , 400 MHz) δ 4.10 (q, $J = 7.1$ Hz, 2H), 3.50 (s, 2H), 2.62 (m, 1H), 2.32 (dd, $J = 14.1$, 8.0 Hz, 2H), 1.86 (dd, $J = 14.0$, 9.8 Hz, 2H), 1.22 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C NMR}$ (CDCl_3 , 100 MHz) δ 174.6, 60.3, 55.9, 37.2, 30.9, 13.9; exact mass (EI) calcd for $(\text{C}_8\text{H}_{12}\text{O}_3)^+$ 156.0786, found 156.0791.

trans-4-[(*tert*-Butyldimethylsilyloxy)methyl]-1,2-epoxycyclopentane (10). Under N_2 , LiAlH_4 (36.2 mL, 36.2 mmol, 1 M in THF) was added in two portions to a cooled (–78 °C) solution of **9** (11.04 g, 70.70 mmol) in dry THF (500 mL). After 4.5 h, the solution was warmed to 0 °C and quenched by the method

(12) Complex **2b** catalyzes the ring opening of epoxides by TMSN_3 with the same enantioselectivity as chloride complex **2a**; however, the use of azide complex **2b** avoids the production of minor amounts of a chloride addition side product observed when catalyst **2a** is used: Leighton, J. L.; Jacobsen, E. N. *J. Org. Chem.* **1996**, *61*, 389.

(13) (a) Liotta, D.; Sunay, U.; Santiesteban, H.; Markiewicz, W. J. *Org. Chem.* **1981**, *46*, 2601. (b) Dowd, P.; Kennedy, P. *Synth. Commun.* **1981**, 935.

(14) For the conversion of **15** to carbovir, see ref 7e.

(15) VanRheenen, V.; Kelly, R. C.; Cha, D. Y. *Tetrahedron Lett.* **1976**, 23, 1973.

(16) For the conversion of **16** to aristeromycin, see: Arita, M.; Adachi, K.; Ito, Y.; Sawai, H.; Ohno, M. *J. Am. Chem. Soc.* **1983**, *105*, 4049.

of Fieser¹⁷ (1.4 mL of H₂O, 1.4 mL of 15% NaOH, and 4.1 mL of H₂O). The solution was allowed to warm to room temperature and filtered through a 1 cm pad of Celite. The Celite pad was washed with hot EtOAc (300 mL), and the combined filtrates were concentrated to give a clear oil (7.82 g, 97%).

Imidazole (10.26 g, 150 mmol) and *tert*-butyldimethylsilyl chloride (11.47 g, 76.1 mmol) were added to a solution of the oil (7.82 g) in CH₂Cl₂ (120 mL). When TLC analysis indicated complete consumption of the starting material, the reaction was diluted with CH₂Cl₂ (150 mL) and the solution was washed with saturated NaHCO₃ (3 × 200 mL). The aqueous layers were combined and extracted with CH₂Cl₂ (3 × 150 mL); the organic layers were combined, washed with saturated NH₄Cl (3 × 200 mL), dried (MgSO₄), and concentrated *in vacuo*. Purification by flash chromatography provided **12** (14.28 g, 91%) as a clear liquid: TLC *R*_f = 0.43 (1:9 EtOAc:hexanes); ¹H NMR (CDCl₃, 400 MHz) δ 3.52 (d, *J* = 5.2 Hz, 2H), 3.44 (s, 2H), 2.04 (dd, *J* = 13.5, 7.6 Hz, 2H), 1.94 (m, 1H), 1.46 (dd, *J* = 13.6, 9.1 Hz, 2H), 0.86 (s, 9H), 0.004 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 64.7, 57.2, 35.4, 30.6, 25.9, 18.3, -5.4; exact mass (EI) calcd for (C₁₂H₂₄O₂Si)⁺ 228.1546, found 228.1552.

(1R,2R,4S)-4-[(*tert*-Butyldimethylsilyloxy)methyl]-2-azido-1-(trimethylsilyloxy)cyclopentane (11). To a solution of (*S,S*)-**6b** (0.94 g, 1.32 mmol) in 20 mL of dry Et₂O was added epoxide **10** (12.1 g, 53.0 mmol) under N₂. After 15 min, TMSN₃ (9.14 g, 79.3 mmol) was added, and the resulting brown solution was stirred at room temperature for 24 h. The reaction mixture was concentrated *in vacuo*, and the residue was filtered through a 3 cm pad of silica gel with 1:4 EtOAc/hexane (150 mL). The filtrate was concentrated and purified by distillation (115–117 °C, 2 Torr) to provide **11** (17.1 g, 94%, 96% ee). Use of the above procedure with catalyst **6a** provided **11** in 91% yield and 96% ee. ¹H NMR (CDCl₃, 400 MHz) δ 3.98 (ddd, *J* = 6.8, 6.8, and 6.8 Hz, 1H), 3.61 (ddd, *J* = 9.0, 7.2 and 6.6 Hz, 1H), 3.46 (d, *J* = 5.5 Hz, 2H), 2.28 (m, 1H), 2.07 (ddd, *J* = 13.2, 8.0, 7.7 Hz, 1H), 1.75–1.60 (m, 2H), 1.33 (ddd, *J* = 13.2, 8.7, 8.9 Hz, 1H), 0.89 (s, 9H), 0.13 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 77.3, 68.5, 66.5, 36.2, 35.3, 31.1, 26.0, 18.3, 0.03, -5.4; exact mass (CI, NH₃) calcd for (C₁₅H₃₃N₃O₂Si₂ + H) 344.2190, found 344.2191.

(1R,2R,4S)-4-[(*tert*-Butyldimethylsilyloxy)methyl]-2-amino-1-(trimethylsilyloxy)cyclopentane (12). A 10 mL flask containing 0.0053 g of palladium on calcium carbonate (Lindlar catalyst, 6.3%) and a solution of **11** (0.08 g, 0.232 mmol) in EtOH (4 mL) was stirred at room temperature under a H₂ atmosphere (1 atm). When TLC analysis indicated complete consumption of the starting azide, the hydrogen atmosphere was displaced by N₂, the reaction was filtered through a 1 cm pad of Celite, and the filtrate was concentrated, providing **12** (0.70 g, 95%) as a clear yellow liquid: ¹H NMR (CDCl₃, 400 MHz) δ 3.62 (ddd, *J* = 7.0, 7.0, and 7.0 Hz, 1H), 3.46 (d, *J* = 5.4 Hz, 2H), 3.00 (ddd, *J* = 9.4, 6.9, 6.0 Hz, 1H), 2.23 (m, 1H), 2.02 (ddd, *J* = 12.8, 8.4, and 7.2 Hz, 1H), 1.74 (ddd, *J* = 12.9, 7.2, and 5.5 Hz, 1H), 1.58 (ddd, *J* = 13.2, 9.9, 7.2 Hz, 1H), 1.08 (ddd, *J* = 12.7, 9.3, 8.5 Hz, 1H), 0.89 (s, 9H), 0.11 (s, 9H), 0.03 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 80.7, 67.0, 60.0, 36.1, 35.3, 34.5, 26.0, 18.4, 0.3, -5.3; exact mass (EI) calcd for C₁₉H₁₈N₄O₃Na 373.1277; found 373.1276.

(1R,2R,4S)-4-[(*tert*-Butyldimethylsilyloxy)methyl]-2-azido-1-(*p*-toluenesulfonyloxy)cyclopentane (13). (1*S*)-(+)-10-camporsulfonic acid (0.264 g, 1.14 mmol) was added to a cooled (0 °C) solution of **11** (19.56 g, 56.92 mmol) in MeOH (190 mL). When TLC analysis indicated complete consumption of the starting material (~10 min), the reaction was quenched by the addition of Et₃N (1 mL), diluted with EtOAc (200 mL), and washed with saturated NaHCO₃ (200 mL) and H₂O (2 × 200 mL). The aqueous layers were combined and extracted with EtOAc (2 × 200 mL). All the organic layers were combined, washed with saturated NH₄Cl (200 mL), dried (MgSO₄), and concentrated *in vacuo*.

To a cooled (0 °C) solution of the residue in CH₂Cl₂ (75 mL) and pyridine (15 mL) was added *p*-toluenesulfonyl chloride (17.2 g, 90.2 mmol), and the mixture was allowed to warm to room temperature. When TLC analysis indicated complete consumption of the starting alcohol, the reaction was diluted with CH₂Cl₂ (100 mL) and washed with saturated NaHCO₃ (2 × 100 mL)

and saturated NH₄Cl (2 × 100 mL). The aqueous layers were combined and extracted with CH₂Cl₂ (2 × 100 mL). The organic extracts were combined and washed with saturated NH₄Cl (2 × 100 mL). The organic layers were combined, dried (MgSO₄), and concentrated under reduced pressure, and flash chromatography of the residue provided **15** (19.62 g, 81%) as a colorless oil: ¹H NMR (CDCl₃, 400 MHz) δ 7.81 (d, *J* = 8.6 Hz, 2H), 7.36 (d, *J* = 8.6 Hz, 2H), 4.59 (ddd, *J* = 5.0, 5.0, and 5.0 Hz, 1H), 3.88 (ddd, *J* = 7.6, 7.6, 4.9 Hz, 1H), 3.46 (dd, *J* = 5.2, 2.0 Hz, 2H), 2.46 (s, 3H), 2.33 (m, 1H), 2.13 (ddd, *J* = 13.6, 8.1, 7.9 Hz, 1H), 1.83 (m, 2H), 1.42 (ddd, *J* = 13.6, 8.0, 7.8 Hz, 1H), 0.87 (s, 9H), 0.01 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 145.0, 130.0, 129.9, 127.9, 85.7, 66.0, 65.5, 37.2, 33.2, 31.3, 25.9, 21.7, 18.2, -5.5; exact mass (FAB, *m*-nitrobenzylalcohol + NaI) calcd for (C₁₉H₃₁O₄N₃Si + Na)⁺ 448.1704, found 448.1702.

(1R,4S)-1-Azido-4-[(*tert*-butyldimethylsilyloxy)methyl]-2-cyclopentene (14). A solution of sodium hydride (0.0056 g, 0.23 mmol) and diphenyl diselenide (0.037 g, 0.12 mmol) in dry THF (3 mL) was allowed to reflux under N₂. After 3 h, HMPA (0.52 g, 0.30 mmol) and **13** (0.067 g, 0.16 mmol) were added, and reflux was resumed under N₂. When TLC analysis indicated complete consumption of the starting material (4.5 h), the reaction was cooled to room temperature, and pyridine (55 μL, 0.68 mmol) and 30% H₂O₂ (0.13 mL) were added to the solution. After 10 h, the reaction was diluted with TBME (15 mL) and washed with H₂O (15 mL) and saturated NaHCO₃ (3 × 10 mL). The organic layer was dried (MgSO₄) and concentrated, and flash chromatography of the oil provided **14** (0.032 g, 81%): ¹H NMR (CDCl₃, 400 MHz) δ 6.03 (ddd, *J* = 5.6, 3.7, 1.9 Hz, 1H), 5.78 (ddd, *J* = 5.6, 4.2, 2.1 Hz, 1H), 4.36 (m, 1H), 3.54 (dd, *J* = 2.0, 6.9 Hz, 2H), 2.86 (m, 1H), 2.39 (ddd, *J* = 14.1, 8.3, 5.9 Hz, 1H), 1.53 (ddd, *J* = 14.1, 9.9, 4.9 Hz, 1H), 0.89 (s, 9H), 0.05 (s, 6H); ¹³C NMR (CDCl₃, 100 MHz) δ 137.9, 129.7, 66.8, 66.7, 47.8, 32.8, 25.9, 18.4, -5.3; exact mass (CI) calcd for (C₁₂H₂₃N₃O₂Si + NH₄)⁺ 271.1956, found 271.1959.

(1R,4S)-1-Amino-4-[(*tert*-butyldimethylsilyloxy)methyl]-2-cyclopentene (15). Under N₂, LiAlH₄ (0.88 mL, 0.88 mmol, 1 M in THF) was added to a cooled (0 °C) solution of **14** (0.20 g, 0.79 mmol) in dry Et₂O (5 mL). When TLC analysis indicated complete consumption of the starting material (1 h), the solution was quenched by the method of Fieser¹⁷ (0.4 mL of H₂O, 0.4 mL of 15% NaOH, and 1 mL of H₂O). The solution was allowed to warm to room temperature and filtered through a 1 cm pad of silica, and the silica pad was washed with hot EtOAc (100 mL). The combined filtrates were concentrated to give **15** (0.70 g, 88%) as a yellow oil: ¹H NMR (CDCl₃, 500 MHz) δ 5.72 (dddd, *J* = 1.7, 5.6, 4.4, 8.2 Hz, 2H), 3.91 (ddd, *J* = 1.5, 5.4, 7.9 Hz, 1H), 3.54 (ddd, *J* = 5.8, 9.8, 19.1 Hz, 2H), 2.76 (m, 1H), 2.40 (ddd, *J* = 5.2, 8.2, 13.4 Hz, 1H), 1.12 (ddd, *J* = 5.6, 5.6, 13.3 Hz, 1H), 0.89 (s, 9H), 0.04 (s, 6H); ¹³C NMR (CDCl₃, 125 MHz) δ 137.0, 133.2, 66.9, 57.8, 47.9, 37.8, 26.0, 18.5, -5.2; exact mass (CI, cool probe) calcd for (C₆H₁₁N₃O + NH₄)⁺ 159.1246, found 159.1242.

(1R,2S,3R,4R)-2,3-Dihydroxy-4-[(*tert*-butyldimethylsilyloxy)methyl]-1-cyclopentanamine (16). A solution of *N*-methylmorpholine *N*-oxide (89 μL, 0.51 mmol, 60% in H₂O) and osmium tetroxide (16 μL, 0.0024 mmol, 0.15 M in H₂O) was added to a cooled (0 °C) solution of **14** (0.062 g, 0.245 mmol) in 1:1 THF/acetone (2.2 mL). When TLC analysis indicated complete consumption of the starting olefin (22 h), the reaction was diluted with CH₂Cl₂ (20 mL) and washed with 10% Na₂SO₃ (20 mL) and NH₄Cl (20 mL). The aqueous layers were combined and extracted with CH₂Cl₂ (2 × 20 mL). The organic layers were combined, dried (MgSO₄), and concentrated, and purification by flash chromatography (1:1 EtOAc:hexanes) provided a yellow oil (0.061 g, 86%).

Under N₂, LiAlH₄ (232 μL, 0.232 mmol, 1 M in THF) was added to a cooled (0 °C) solution of the oil (0.061 g, 0.211 mmol) in dry Et₂O (1.3 mL). When TLC analysis indicated complete consumption of the starting material (1 h), the solution was quenched by the method of Fieser¹⁷ (9 μL of H₂O, 9 μL of 15% NaOH, and 27 μL of H₂O). The solution was allowed to warm to room temperature and filtered through a 1 cm pad of Celite. The Celite pad was washed with hot EtOAc (50 mL), and the combined filtrates were concentrated to give **16** (0.048 g, 87%) as a yellow oil: ¹H NMR (CDCl₃, 500 MHz) δ 3.97 (dd, *J* = 5.0, 10.0 Hz, 1H), 3.75 (dd, *J* = 4.0, 9.9 Hz, 1H), 3.68 (dd, *J* = 5.8, 11.5 Hz, 1H), 3.61 (dd, *J* = 5.6, 11.1 Hz, 1H), 3.55 (ddd, *J* = 6.1,

(17) Fieser, L. F.; Fieser, M. *Reagents for Organic Synthesis*; John Wiley and Sons: New York, 1967; Vol. 1, p 584.

6.1, 3.6 Hz, 1H), 2.08–2.14 (m, 2H), 1.02 (m, 1H), 0.89 (s, 9H), 0.06 (s, 6H); ^{13}C NMR (CDCl_3 , 125 MHz) δ 77.1, 74.9, 65.4, 65.0, 44.7, 28.9, 25.9, 18.3, -5.5; exact mass (FAB, *m*-nitrobenzyl alcohol + NaI) calcd for $(\text{C}_{12}\text{H}_{27}\text{O}_3\text{NSi} + \text{H})^+$ 262.1838, found 262.1839.

Acknowledgment. This work was supported by the National Institutes of Health (GM-43214). We thank

Dr. J. L. Leighton and Ms. T. C. Chin for preliminary experimental work, Dr. D. Taber for providing the procedure to synthesize compound 7, and the Ford Foundation for a graduate fellowship to L.E.M.

JO961241L